BACKGROUND AND PURPOSE: Spectroscopic examination of multiple sclerosis (MS)
patients has revealed abnormally low n-acetyl-aspartate (NAA) signal intensity, even in …

Background Whole-brainN-acetyl aspartate (NAA), a measure of neuronal function, can be
assessed by multislice echo-planar spectroscopic imaging. Objective To test the hypothesis …

BACKGROUND AND PURPOSE: Neuro-axonal damage is a well known sequelae of MS
pathogeneses. Consequently, our aim was to test whether the∼ 20% of patients with MS …

BACKGROUND AND PURPOSE: The T2-weighted MR imaging total lesion volume and
Expanded Disability Status Scale (EDSS) score are two common measures of relapsing …

Previous in vivo proton magnetic resonance spectroscopic imaging (1 H–MRSI) studies
have found reduced levels of N–acetyl–aspartate (NAA) in multiple sclerosis (MS) lesions …

PURPOSE: To quantify the rate of concentration decline of neuronal marker N-
acetylaspartate (NAA) in the entire brain of patients with relapsing-remitting multiple …

The concentration of the metabolite N-acetyl aspartate (NAA), thought to be a marker of
axonal loss or damage, has been shown to be reduced in lesions, as demonstrated by high …

MR spectroscopy (MRS) provides information about neuronal loss or dysfunction by
measuring decreases in N‐acetyl aspartate (NAA), a metabolite widely believed to be a …

Objectives: To test the hypotheses that 1) patients with relapsing-remitting multiple sclerosis
(RR-MS) exhibit a quantifiable decline in their whole-brain concentration of the neural …

Objective: To characterize and follow the diffuse gray and white matter (GM/WM) metabolic
abnormalities in early relapsing-remitting multiple sclerosis using proton magnetic …